SLFN12

Across TCGA pan-cancer cohorts, SLFN12 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SLFN12 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher SLFN12 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated SLFN12 expression acts as an unfavorable survival marker, although some lineages such as SKCM and UCEC show a favorable association.

SKCM, UCEC, and ESCA are the cancer types where SLFN12 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	II,III,IV	1.000	0.675	.002	27	view →
UCEC	DFS	Median	All	1.000	0.628	.016	16	view →
ESCA	OS	Median	All	0.147	0.700	.005	6	view →
LIHC	OS	Median	All	0.015	0.784	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SLFN12–SKCM (DFS)

Open the SKCM breakdown →